Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare.

Angiocrine Bioscience has developed a cellular platform for amplifying stem and progenitor cells, in both human and mouse models, by recapitulating the proliferative stimulation of the in vivo vascular niche in vitro. The expansion capacity is on an unprecedented scale when compared to any other competing technology, and it is achieved without the requirement for costly media additives. This process can meet the needs of a broad range of therapeutic, diagnostic, and research applications. We look forward to the expansive application of this technology to help fulfill the promise of tissue-specific engineering and organ-regeneration.

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.

GAIA BioMedicine, Inc., a technology-driven biopharmaceutical firm specialized in cell treatments and immunotherapies for intractable malignancies, was created in 2015 as a spin-off venture of Kyushu University. The firm name, GAIA, reflects the company's aim and vision as we fight intractable diseases with the strength of genes and the immune system as the rod of Asclepius, the Greek god of medicine.

Tianjin Xiehe Biotechnology Development Co., Ltd., established on 1992-07-23, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D and application of cell technology;Human stem cell technology development and application;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Intellectual Property Services;Technology intermediary service;Conference and Exhibition Services;Sales of building materials;Auto Parts Wholesale;electric wire,cable management;Electrical Equipment Sales;Wholesale of hardware products;Hardware retail;Sales of building decoration materials;General merchandise sales;Stationery Wholesale,Stationery retail;Office Supplies Sales;food business(Only sell prepackaged food);property management;Information Consulting Service(Not including licensing information consulting services);Business Management Consulting;business management;Health Consulting Services(Does not include medical services);Labor service(Does not include labor dispatch).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:accommodation service;Tobacco retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Hemodyne, Inc. engages in the provision of medical devices. The company was founded by Marcus E. Carr on August 15, 2006 and is headquartered in Bethesda, MD.

Hôpital Maisonneuve-Rosemont is a hospital in Montreal, Quebec, Canada, located in the borough of Rosemont–La Petite-Patrie. It serves the eastern part of the city and offers 700 beds. It employs 5,000 people and 3,000 students annually. It is the largest hospital in Quebec.

Centro Nacional de Investigaciones Cardiovasculares is a private company headquartered in Madrid, Spain. The firm engages in research and development of social sciences.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. It involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Hospital Clínic de Barcelona is a Spanish private company located in Barcelona. The firm operates hospital. Josep Maria Campistol is currently the CEO of the company.\nThe company says this about itself: Hospital Clínic of Barcelona is a public university hospital with a centuries-long history. With 4500 employees, it is one of the leading healthcare centers in Spain and the first in scientific production. The hospital offers quality care, high-level excellence, and competitive biomedical research and a strong teaching commitment to train professionals. All of this is included in an excellent balanced management with the aim of offering society a humanized, cutting-edge medicine.